Domainex expands Executive and Management Teams to support ongoing growth

Cambridge, UK, 15th November 2022 / Sciad Newswire / Domainex Ltd., a leading provider of integrated drug discovery services, is pleased to announce that it has made a number of strategic internal promotions to strengthen its Executive and Management teams. This expansion marks a period of ongoing growth for Domainex, and the newly bolstered teams will be pivotal in driving further development of the company.

Dr Natalie Winfield and Dr Catherine Stace immediately join the Executive Team, with Natalie taking on the position of Executive Director of Commercial Operations and Catherine the position of Executive Director of Business Development. Natalie has been with Domainex for almost 18 years, initially joining as a medicinal chemist in 2005. Having progressed to Medicinal Chemistry Team Leader, she transitioned into the commercial field in 2018, initially as Products and Contracts Manager and subsequently as Director of Commercial Operations. Catherine joined Domainex in 2019 as Director of Business Development and has over 16 years of industry experience having previously worked for several Biotech companies, including XenoVida, Cancer Targeting Systems, Bicycle Therapeutics and Isogenica. Catherine and Natalie have a wealth of scientific and commercial experience, and their appointments will strengthen the Executive Team and further support Domainex’s ongoing growth plans.

Additionally, David Cronk has taken on the new role of Chief Operating Officer, having joined Domainex as Chief of Staff in 2021. Dr Ray Boffey has taken on additional responsibility for strategic alliances with the new title of Executive Director of Medicines Research & Strategic Alliances.

Changes to the scientific management structure have also taken effect with the promotions of Dr Andrew Ratcliffe to Head of Chemistry, Dr Trevor Askwith to Head of Biology and Dr Scott Martin to Head of Bioanalytical Sciences. Andrew joined Domainex in 2019 and has over 30 years of drug discovery experience. He has held multiple leadership roles, including Head of Chemistry at Redx Anti-infectives, culminating in nominating several small molecule candidates, one of which progressed to Phase II clinical trials. Trevor joined Domainex in 2020 and previously held the role of Head of Assay Development and Screening for the Drug Discovery Group at UCL. Scott has 25 years of experience in bioanalytical sciences within drug discovery and development, predominantly gained in large pharma.

Dr Tom Mander, CEO of Domainex, commented, “As Domainex continues to grow, we must have the right team in place to support the expansion. These new appointments will strengthen the Executive and Management Teams, ensuring that we continue to provide a first-class service to our clients and a great working environment for our team.”


Notes to Editors
About Domainex Ltd.
Domainex is a leading, multi-award-winning, integrated medicines research service partner working with ambitious life science organisations from around the globe. The Company has been setting new standards in research since 2001, working collaboratively with pharmaceutical and biotechnology companies, patient foundations and leading academic institutions globally.

Domainex provides innovative and customised biology and chemistry services to advance the disease research projects of its partners, from target expression to pre-clinical development candidate nomination. Working with Domainex maximises the chance of successful progression for its partners’ research. Domainex’s innovative science and extensive technical capabilities enable it to produce novel candidate medicines to treat debilitating diseases. The team works closely and collaboratively with its partners to understand their aspirations, bringing ideas, know-how and a wealth of experience to bear on their projects.

Domainex’s highly qualified and experienced team of dedicated research scientists has an unrivalled breadth of knowledge, access to a wide range of technologies and a proven track record of successful innovation in solving research challenges, including being named on over 60 patent applications of numerous candidate drugs. The company aims to deliver successful outcomes efficiently and quickly, setting the highest possible benchmark in medicines research.

Full information about Domainex and its award-winning services can be found at

Media Contact Information: 

For more information, contact:
Dr Tom Mander, CEO

Sciad Communications
Juliette Craggs / Darya Shulakova
T: +44 (0)20 3405 7892